Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.800
-0.037 (-4.41%)
Apr 29, 2026, 10:25 AM EDT - Market open
Aprea Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -12.6 | -12.96 | -14.29 | -112.66 | -37.13 | |
| Depreciation & Amortization | 0.02 | 0.02 | 0.01 | 0.19 | 0.27 | |
| Asset Writedown & Restructuring Costs | - | - | - | 72.52 | - | |
| Stock-Based Compensation | 0.52 | 0.51 | 0.44 | 16.98 | 7.81 | |
| Other Operating Activities | 0.1 | -0.07 | 0.04 | -0.28 | -0.32 | |
| Change in Accounts Payable | -0.65 | -0.31 | 0.83 | -0.86 | -2.73 | |
| Change in Unearned Revenue | - | -0.53 | 0.53 | - | - | |
| Change in Other Net Operating Assets | -0.28 | -0.21 | 0.26 | -0.9 | -5.6 | |
| Operating Cash Flow | -12.89 | -13.56 | -12.18 | -25.01 | -37.69 | |
| Capital Expenditures | - | -0.02 | -0.09 | - | - | |
| Investing Cash Flow | - | -0.02 | -0.09 | - | - | |
| Issuance of Common Stock | 5.05 | 16.14 | 5.79 | 0.68 | 1.75 | |
| Other Financing Activities | -0.41 | -1.32 | -0.65 | - | - | |
| Financing Cash Flow | 4.64 | 14.82 | 5.14 | 0.68 | 1.75 | |
| Foreign Exchange Rate Adjustments | 0 | -0.01 | -0.01 | 0.04 | -0 | |
| Net Cash Flow | -8.25 | 1.24 | -7.14 | -24.29 | -35.94 | |
| Free Cash Flow | -12.89 | -13.57 | -12.27 | -25.01 | -37.69 | |
| Free Cash Flow Margin | -4512.35% | -903.26% | -2103.92% | - | - | |
| Free Cash Flow Per Share | -1.97 | -2.46 | -3.39 | -15.09 | -35.41 | |
| Levered Free Cash Flow | -8.56 | -9.27 | -7.67 | -7.97 | - | |
| Unlevered Free Cash Flow | -8.56 | -9.27 | -7.67 | -7.97 | - | |
| Change in Working Capital | -0.93 | -1.06 | 1.62 | -1.76 | -8.33 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.